What is the recommended treatment for a woman with Candida albicans vaginitis who has failed multiple courses of oral fluconazole?

Treatment of Fluconazole-Resistant Candida albicans Vulvovaginitis

For a woman with confirmed Candida albicans vaginitis who has failed multiple courses of oral fluconazole, intravaginal boric acid 600 mg daily for 14 days is the most effective treatment option. 1

Diagnostic Confirmation Before Treatment

Before initiating therapy for fluconazole-resistant disease, confirm the diagnosis and species:

• Perform wet-mount microscopy with 10% potassium hydroxide to visualize pseudohyphae characteristic of C. albicans (distinguishing it from C. glabrata, which does not form pseudohyphae). 1
• Measure vaginal pH, which should be 4.0–4.5 in candidiasis; elevated pH suggests bacterial vaginosis or trichomoniasis instead. 1
• Obtain fungal culture with species identification and antifungal susceptibility testing to confirm C. albicans and document fluconazole resistance (MIC ≥8 μg/mL). 2, 3

Primary Treatment Recommendation

Intravaginal boric acid 600 mg in a gelatin capsule, inserted once daily at bedtime for 14 consecutive days, is the endorsed first-line therapy for azole-refractory vulvovaginal candidiasis. 1

Important Context About Boric Acid

• The IDSA 2016 guidelines provide a strong recommendation (low-quality evidence) for boric acid, though this recommendation was originally directed at C. glabrata infections unresponsive to oral azoles. 1
• Despite this caveat, boric acid has emerged as the definitive treatment of choice for fluconazole-resistant C. albicans vaginitis in clinical practice, particularly given the limited alternatives and documented clinical success. 4
• Fluconazole resistance in C. albicans is an emerging problem, with increased consumption of fluconazole (especially low-dose weekly maintenance therapy) being the primary risk factor. 2

Alternative Second-Line Options

If boric acid is unavailable, ineffective, or not tolerated:

• Nystatin intravaginal suppositories 100,000 units daily for 14 days (strong recommendation; low-quality evidence). 1
• Topical 17% flucytosine cream alone or combined with 3% amphotericin B cream daily for 14 days (weak recommendation; low-quality evidence). 1

Systemic Azole Alternatives for Fluconazole-Refractory Disease

The IDSA guidelines recommend systemic alternatives for fluconazole-refractory oropharyngeal and esophageal candidiasis that may be considered for severe or complicated vulvovaginal cases:

• Itraconazole solution 200 mg once daily for up to 28 days (strong recommendation; moderate-quality evidence). 5
• Posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days (strong recommendation; moderate-quality evidence). 5
• Voriconazole 200 mg twice daily (strong recommendation; moderate-quality evidence). 5

However, these systemic options are less well-studied for vulvovaginal candidiasis specifically and should be reserved for severe, refractory cases where local therapy has failed. 6

Critical Pitfalls to Avoid

• Do not treat empirically without confirming candidiasis; vulvovaginal symptoms are nonspecific and may arise from multiple infectious or non-infectious causes. 1
• Fluconazole resistance in C. albicans is often persistent and rarely reverses even after prolonged azole avoidance (only 5.2% of resistant isolates reverted to susceptible in longitudinal follow-up). 7
• Avoid continued fluconazole use once resistance is documented, as this perpetuates treatment failure and may worsen resistance patterns. 2, 3
• Recognize that in vitro susceptibility does not always predict clinical response; even isolates showing in vitro susceptibility to itraconazole may fail clinically. 4

Management of Recurrent Disease

If the patient has recurrent vulvovaginal candidiasis (≥4 episodes per year) with fluconazole-susceptible isolates:

• Induction therapy with 10–14 days of topical azole or oral fluconazole 150 mg on days 1,4, and 7, followed by maintenance therapy with fluconazole 150 mg weekly for 6 months. 1
• This regimen assumes the isolate remains fluconazole-susceptible; do not use maintenance fluconazole if resistance is documented. 1

For patients with documented fluconazole-resistant recurrent disease, chronic suppressive therapy options are extremely limited, and intermittent boric acid therapy may be required, though optimal dosing schedules for suppression are not well-established. 6